Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of KEYNOTE-010 trial

(2019) R S Herbst et al.   ANNALS OF ONCOLOGY

Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society

(2018) Erik Thunnissen et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer

(2018) Ji Hyun Yang et al.   Gastric Cancer

Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments

(2018) Shota Omori et al.   International Journal of Clinical Oncology

PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

(2018) Haidong Tang et al.   JOURNAL OF CLINICAL INVESTIGATION

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial

(2018) Vasiliki Pelekanou et al.   MOLECULAR CANCER THERAPEUTICS

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis

(2018) Ross A. Soo et al.   Oncotarget

Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

(2018) Edwin R. Parra et al.   Journal for ImmunoTherapy of Cancer

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

(2018) Jean-David Fumet et al.   BRITISH JOURNAL OF CANCER

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

(2018) Giulia Mazzaschi et al.   LUNG CANCER

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

(2018) Marcin Kowanetz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy

(2017) Thomas J Gniadek et al.   MODERN PATHOLOGY

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL INVESTIGATION

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Testing for ROS1 in non-small cell lung cancer: a review with recommendations

(2016) Lukas Bubendorf et al.   VIRCHOWS ARCHIV

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Stromal CD8+ T-cell Density--A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer

(2015) T. Donnem et al.   CLINICAL CANCER RESEARCH

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

(2014) A. R. de Biasi et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Impact of Collection and Storage of Lung Tumor Tissue on Whole Genome Expression Profiling

(2012) Maxim B. Freidin et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET

(2012) Guus A. M. S. van Dongen et al.   TUMOR BIOLOGY

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis

(2007) Ping Zhang et al.   MOLECULAR IMMUNOLOGY